BRKR heads into the final days of June with a split personality: a stock that has gained 21% in a month yet is attracting more short sellers, while options traders have rarely been less worried about downside.
The positioning picture here contains a genuine tension. Short interest has climbed roughly 22% over the past month to 9.7% of free float — a meaningful level for a large-cap life sciences name — and rose 5% on the week even as the broader market stabilised. That month-long build has coincided almost perfectly with BRKR's 21% price rally off its May lows, suggesting short sellers are actively fading the recovery rather than covering into it. The ORTEX short score has crept higher all week, reaching 68.1 on Tuesday after touching 71.5 on Monday, its highest recent reading. One mitigating factor: borrow conditions remain relaxed. Availability is running at roughly 211% — more than two shares available for every one currently borrowed — and cost to borrow has barely moved, holding near 0.6%. That means the short build is happening in a well-supplied lending market, with no squeeze pressure whatsoever on the horizon.
Options traders, however, are telling a completely different story. The put/call ratio has collapsed to just 0.16, less than half its 20-day average of 0.35, and is running near the lowest reading of the past year (the 52-week low is 0.14). The z-score of -1.25 confirms how far demand for downside protection has drained away. Back in May, when the stock was trading in the mid-$30s, the PCR was running above 0.7 — a period of heavy hedging that has now unwound entirely. Call buying has taken over. Options markets are positioned for further gains; short sellers are betting on a reversal. Those two signals rarely sit more comfortably apart than they do right now in BRKR.
The Street has turned modestly more constructive, and the timing is notable. Barclays raised its target to $60 from $53 this morning — the second consecutive upward revision from the firm after it cut to $45 in mid-April — while JP Morgan lifted to $65 from $55 earlier in June, both keeping Overweight ratings. That puts the two most active bulls well above the consensus mean of $53.83, which already sits slightly below the current price of $55.11. Some broader caution persists: UBS and Citigroup both raised targets after Q1 results in early May but held at $44-$45 with Neutral ratings, and Wolfe Research initiated at Peer Perform with no target. The forward earnings picture helps explain the bullish upgrades — BRKR ranks in the 91st percentile for 12-month forward EPS growth expectations. But actual earnings surprise history is weak at just the 8th percentile, and value remains stretched with a trailing P/E near 25x and price-to-book at 3.4x, up roughly 0.6x over the past month as the stock re-rated. The bull case centres on constant-currency EPS growth of 5-8% and improving gross margins; the bear case rests on a meaningful margin guide-down for FY25 and flagging organic growth in the US and China.
On ownership, the register is tightly held by the Laukien family — founder Frank Laukien holds 26.5% and his brother Joerg a further 5% — which constrains the float meaningfully. Orbis Investment Management and FMR have both added materially in recent quarters, building positions above 11% and 7% respectively. Insider activity is low-drama: the only recent trades are routine monthly sells from a divisional president, each around 2,000 shares, with the latest on June 15 at $54.76.
The next scheduled earnings event is August 5. After Q1 results in May, BRKR moved 15% higher on the day and extended that to a 15% five-day gain — a strong recent reaction that explains some of the current call-dominated options setup. What to watch between now and then is whether the short rebuild continues to push the ORTEX short score back toward the mid-70s, and whether analyst consensus mean targets can close the gap with Barclays' and JP Morgan's more aggressive marks — or whether the bears fading the rally start to look better-positioned as the August print approaches.
See the live data behind this article on ORTEX.
Open BRKR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
